Literature DB >> 23277329

The Fc-engineered CD19 antibody MOR208 (XmAb5574) induces natural killer cell-mediated lysis of acute lymphoblastic leukemia cells from pediatric and adult patients.

C Kellner, E A Zhukovsky, A Pötzke, M Brüggemann, A Schrauder, M Schrappe, M Kneba, R Repp, A Humpe, M Gramatzki, M Peipp.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23277329     DOI： 10.1038/leu.2012.373

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  19 in total

Review 1.  Next generation antibody drugs: pursuit of the 'high-hanging fruit'.

Authors:  Paul J Carter; Greg A Lazar
Journal:  Nat Rev Drug Discov       Date:  2017-12-01       Impact factor: 84.694

Review 2.  Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy.

Authors:  Christian Kellner; Anna Otte; Elisa Cappuzzello; Katja Klausz; Matthias Peipp
Journal:  Transfus Med Hemother       Date:  2017-09-08       Impact factor: 3.747

Review 3.  Antibody-mediated protection against Ebola virus.

Authors:  Erica Ollmann Saphire; Sharon L Schendel; Bronwyn M Gunn; Jacob C Milligan; Galit Alter
Journal:  Nat Immunol       Date:  2018-10-17       Impact factor: 25.606

4.  Reduction of Minimal Residual Disease in Pediatric B-lineage Acute Lymphoblastic Leukemia by an Fc-optimized CD19 Antibody.

Authors:  Ursula Jördis Eva Seidel; Patrick Schlegel; Ludger Grosse-Hovest; Martin Hofmann; Steffen Aulwurm; Elwira Pyz; Friedhelm R Schuster; Roland Meisel; Martin Ebinger; Tobias Feuchtinger; Heiko-Manuel Teltschik; Kai-Erik Witte; Carl-Philipp Schwarze; Hans-Georg Rammensee; Rupert Handgretinger; Gundram Jung; Peter Lang
Journal:  Mol Ther       Date:  2016-07-06       Impact factor: 11.454

5.  Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies.

Authors:  Ursula J E Seidel; Patrick Schlegel; Peter Lang
Journal:  Front Immunol       Date:  2013-03-27       Impact factor: 7.561

6.  DNA damage response and evasion from immunosurveillance in CLL: new options for NK cell-based immunotherapies.

Authors:  Olga M Shatnyeva; Hinrich P Hansen; Katrin S Reiners; Maike Sauer; Maulik Vyas; Elke Pogge von Strandmann
Journal:  Front Genet       Date:  2015-02-04       Impact factor: 4.599

7.  γδ T Cell-Mediated Antibody-Dependent Cellular Cytotoxicity with CD19 Antibodies Assessed by an Impedance-Based Label-Free Real-Time Cytotoxicity Assay.

Authors:  Ursula Jördis Eva Seidel; Fabian Vogt; Ludger Grosse-Hovest; Gundram Jung; Rupert Handgretinger; Peter Lang
Journal:  Front Immunol       Date:  2014-12-02       Impact factor: 7.561

8.  Cytotoxicity of CD56-positive lymphocytes against autologous B-cell precursor acute lymphoblastic leukemia cells.

Authors:  F Fei; M Lim; A A George; J Kirzner; D Lee; R Seeger; J Groffen; H Abdel-Azim; N Heisterkamp
Journal:  Leukemia       Date:  2014-08-19       Impact factor: 11.528

9.  CD19-specific triplebody SPM-1 engages NK and γδ T cells for rapid and efficient lysis of malignant B-lymphoid cells.

Authors:  Christian B Schiller; Todd A Braciak; Nadja C Fenn; Ursula J E Seidel; Claudia C Roskopf; Sarah Wildenhain; Annemarie Honegger; Ingo A Schubert; Alexandra Schele; Kerstin Lämmermann; Georg H Fey; Uwe Jacob; Peter Lang; Karl-Peter Hopfner; Fuat S Oduncu
Journal:  Oncotarget       Date:  2016-12-13

10.  A novel Fc-engineered human ICAM-1/CD54 antibody with potent anti-myeloma activity developed by cellular panning of phage display libraries.

Authors:  Katja Klausz; Michael Cieker; Christian Kellner; Hans-Heinrich Oberg; Dieter Kabelitz; Thomas Valerius; Renate Burger; Martin Gramatzki; Matthias Peipp
Journal:  Oncotarget       Date:  2017-09-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.